Discover 1,567 paid clinical trials in Jersey City, New Jersey. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,567
Featured
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
for
Non Small Cell Lung Carcinoma
Location: East Brunswick NJ, Easton PA, Shirley NY, Boston MA,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06772623
Phase1, Phase2, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
for
Non-Small Cell Lung Cancer
Location: East Brunswick NJ, Lebanon NH, Brampton, Fort Wayne IN,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07155187
Phase2, Phase3, Recruiting
Featured
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
for
Breast Cancer
Location: East Brunswick NJ, Jacksonville FL, Kansas City MO,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07368998
Phase2, Recruiting
Featured
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
for
HER2-positive Breast Cancer
Location: East Brunswick NJ, Shirley NY, Albany NY, Montreal,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07413939
Phase2, Phase3, Recruiting
Active & Responsive
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
for
Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms,
Location: Jersey City NJ, Newark NJ, Belleville NJ, Elizabeth NJ,
Sponsor: Rutgers, The State University of New Jersey
Sex: All
Age: 18+
Code: NCT07158164
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
for
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver,
Location: New York NY, Staten Island NY, Hempstead NY,
Sponsor: Massive Bio, Inc.
Sex: All
Age: 0+
Code: NCT03452774
Recruiting
Active & Responsive
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
for
Psoriasis, Overweight or Obesity
Location: Hoboken NJ, New York NY, East Windsor NJ,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06857942
Recruiting
Active & Responsive
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Location: New York NY, Newark NJ, Staten Island NY, Rego Park NY,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT07198074
Phase3, Recruiting
Active & Responsive
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
for
Recurrent Head and Neck Squamous Cell Carcinoma,
Location: New York NY, The Bronx NY, Montvale NJ, Uniondale NY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT04671667
Phase2, Recruiting
Active & Responsive
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
for
Ductal Carcinoma in Situ
Location: New York NY, Englewood NJ, Richmond VA, Durham NC,
Sponsor: QuantumLeap Healthcare Collaborative
Sex: Female
Age: 18+
Code: NCT06075953
Phase2, Recruiting
Active & Responsive
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
for
Metastatic Head and Neck Squamous Cell Carcinoma,
Location: New York NY, Newark NJ, Providence RI, Baltimore MD,
Sponsor: Bicara Therapeutics
Sex: All
Age: 18+
Code: NCT06788990
Phase2, Phase3, Recruiting
Active & Responsive
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
for
Geographic Atrophy Secondary to Age-related Macular Degeneration,
Location: New York NY, Toms River NJ, Philadelphia PA, Boston MA,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 50+
Code: NCT07441642
Phase2, Recruiting
Active & Responsive
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Location: New York NY, Morristown NJ, New Brunswick NJ,
Sponsor: Chris Goss
Sex: All
Age: 6+
Code: NCT05548283
Recruiting
Active & Responsive
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
for
NASH - Nonalcoholic Steatohepatitis,
Location: New York NY, Manhasset NY, Sparta NJ, Jackson NJ,
Sponsor: Akero Therapeutics, Inc
Sex: All
Age: 18 - 70+
Code: NCT06528314
Phase3, Recruiting
Active & Responsive
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
for
NASH With Fibrosis, MASH With Fibrosis
Location: New York NY, Ridgewood NJ, Manhasset NY, Sparta NJ,
Sponsor: Akero Therapeutics, Inc
Sex: All
Age: 18 - 70+
Code: NCT06215716
Phase3, Recruiting
Active & Responsive
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
for
Diabetes Mellitus, Type 2, Hypertension,
Location: New York NY, Linden NJ, Somerset NJ, Bridgewater NJ,
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT07064473
Phase3, Recruiting
Active & Responsive
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: New York NY, Hackensack NJ, New Brunswick NJ,